Table 1: (a) The characteristics of the nine studies, (b) Efficacy indices.
(a)

ReferenceTotal number
(Paricalcitol/placebo)
Etiology of CKD
DMno DM Treatment Dosing regimen Route of administration Age

[4]55 (28/27)26296-month1 ug/d and 2 ug/dOral18–85
[5]24 (16/8)13111-month1 ug/d and 2 ug/dOral>18
[6]118 (57/61)79424-week1 ug/d and 2 ug/d or 2 ug TIW and 4 ug TIWOral≥18
[7]78 (40/38)12-week0.04 ug/kg TIWIntravenous22–90
[8] TIW145 (72/73)885724-week2 ug TIW and 4 ug TIWOral≥18
[8] QD75 (35/40)413424-week1 ug/d and 2 ug/dOral≥18
[9]220 (107/113)1299124-week1 ug/d and 2 ug/d or 2 ug TIW and 4 ug TIWOral≥18
[10]29 (15/14)12-week0.04 ug/kg or 0.08 ug/kg TIWIntravenous2–20
[11]88 (61/27)12-weekiPTH/60 TIWOral≥18
[12]281 (186/95)272024-week1 ug/d and 2 ug/dOral>20

Reference [8] had different methods of administration and gave us the information, respectively.
TIW: treatment with Paricalcitol or placebo thrice weekly.
QD: treatment with Paricalcitol or placebo once a day.
(b)

Reference[4][5][6][7][8] (TIW)[8] (QD)[9][10][11][12]Total number
(P/p)

Total number of patients (P/p)55
(28/27)
24
(16/8)
118
(57/61)
78
(40/38)
145
(72/73)
75
(35/40)
220
(107/113)
29
(15/14)
88
(61/27)
281
(186/95)
1113
(617/496)
30% decrease in iPTH levels for two consecutive measures (P/p)113
(54/59)
78
(40/38)
138
(68/70)
71
(33/38)
209
(101/108)
29
(15/14)
82
(58/24)
720
(369/351)
Mean eGFR change from baseline to the final visit (P/p)118
(57/61)
117
(57/60)
58
(25/33)
175
(82/93)
468
(221/247)
Incidence of hypercalcemia (P/p)55
(28/27)
140
(69/71)
74
(35/39)
209
(101/108)
29
(15/14)
87
(61/26)
281
(186/95)
875
(495/380)
Incidence of hyperphosphatemia (P/p)55
(28/27)
140
(69/71)
74
(35/39)
209
(101/108)
478
(233/245)
Elevation in Ca × P product levels (P/p)140
(69/71)
74
(35/39)
209
(101/108)
423
(205/218)
Reduction in proteinuria55
(28/27)
22
(15/7)
272
(184/88)
349
(227/122)

P: Paricalcitol group; p: placebo group.